Mustang Bio Inc (MBIO) Shares Decline Despite Market Challenges

Mustang Bio Inc (NASDAQ: MBIO)’s stock price has gone decline by -19.61 in comparison to its previous close of 1.02, however, the company has experienced a -11.92% decrease in its stock price over the last five trading days. GlobeNewsWire reported 2023-09-07 that WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City.

Is It Worth Investing in Mustang Bio Inc (NASDAQ: MBIO) Right Now?

Moreover, the 36-month beta value for MBIO is 1.53. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The public float for MBIO is 7.58M and currently, short sellers hold a 5.13% of that float. On April 04, 2024, MBIO’s average trading volume was 143.35K shares.

MBIO’s Market Performance

MBIO’s stock has seen a -11.92% decrease for the week, with a -39.26% drop in the past month and a -37.88% fall in the past quarter. The volatility ratio for the week is 13.42%, and the volatility levels for the past 30 days are at 13.54% for Mustang Bio Inc The simple moving average for the past 20 days is -24.80% for MBIO’s stock, with a -67.16% simple moving average for the past 200 days.

Analysts’ Opinion of MBIO

Many brokerage firms have already submitted their reports for MBIO stocks, with BTIG Research repeating the rating for MBIO by listing it as a “Buy.” The predicted price for MBIO in the upcoming period, according to BTIG Research is $11 based on the research report published on May 18, 2021 of the previous year 2021.

B. Riley FBR, on the other hand, stated in their research note that they expect to see MBIO reach a price target of $9. The rating they have provided for MBIO stocks is “Buy” according to the report published on October 02nd, 2020.

Cantor Fitzgerald gave a rating of “Overweight” to MBIO, setting the target price at $7 in the report published on November 20th of the previous year.

MBIO Trading at -33.91% from the 50-Day Moving Average

After a stumble in the market that brought MBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.96% of loss for the given period.

Volatility was left at 13.54%, however, over the last 30 days, the volatility rate increased by 13.42%, as shares sank -39.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.15% lower at present.

During the last 5 trading sessions, MBIO fell by -11.92%, which changed the moving average for the period of 200-days by -88.78% in comparison to the 20-day moving average, which settled at $1.0640. In addition, Mustang Bio Inc saw -39.26% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for MBIO

The total capital return value is set at -20.82. Equity return is now at value -222.44, with -93.68 for asset returns.

Based on Mustang Bio Inc (MBIO), the company’s capital structure generated 0.95 points at debt to capital in total, while cash flow to debt ratio is standing at -19.81. The debt to equity ratio resting at 20.31. The interest coverage ratio of the stock is -37.81.

Currently, EBITDA for the company is -48.5 million with net debt to EBITDA at 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.

Conclusion

To wrap up, the performance of Mustang Bio Inc (MBIO) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts